Loading...
•
Mar 31, 2024
Omnicell Q1 2024 Earnings Report
Omnicell's Q1 2024 results exceeded prior guidance across all metrics
Key Takeaways
Omnicell announced its first quarter 2024 results, exceeding prior guidance across all key metrics including revenue, non-GAAP EBITDA, and non-GAAP earnings per share. Total GAAP revenues were $246 million, a decrease of 15% compared to the first quarter of 2023. The company reported a GAAP net loss of $16 million, or $0.34 per diluted share, and a non-GAAP net income of $1 million, or $0.03 per diluted share.
Introduced XT Amplify, innovative solutions designed to enhance pharmacy and nursing efficiency and reduce medication errors.
Hosted Illuminate 2024 educational and networking event.
Published the 2023 Environmental, Social, and Governance Report (ESG).
Progressed holistic review of business to identify areas for operational and financial improvement.
Revenue by Segment
Forward Guidance
The Company’s full year 2024 guidance is unchanged. For the second quarter of 2024, the Company expects total revenues to be between $250 million and $260 million.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...